The Treatment Efficacy of Prolotherapy in Bladder Voiding Dysfunction
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Overactive Bladder
- Sponsor
- Taichung Armed Forces General Hospital
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- Overactive Bladder Symptom Score
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
Voiding dysfunction including overactive bladder, underactive bladder, and neuropathic bladder. Voiding dysfunction has a great impact on life quality, especially in the elderly society. The current medication for overactive bladder has limited efficacy and the patient easily to dropout the medication because of its side-effects. The underactive bladder is a new entity of voiding dysfunction, its optimal is still unknown. Sacral neuromodulation(SNM) and posterior tibial nerve stimulation(PTNS) have been applied for both overactive bladder and underactive bladder treatment and the results is promising, but the equipment of SNM or PTNS is not available in most places. Prolotherapy using glucose local injection causing inflammatory reaction to stimulate cytokine and growth factors release. Investigators combined the concepts of posterior tibial nerve stimulation and prolotherapy to treat voiding dysfunction. Investigators anticipate it maybe a new promising treatment for voiding dysfunction.
Detailed Description
Inclusion criteria:1. Adults over 20 years-old. 2. The patient who meets the diagnostic criteria of overactive bladder or underactive bladder. 3. The patient who capable to complete 3-days voiding diary and the questionnaire. Exclusion criteria: 1. The patient has severe stress urinary incontinence, severe pelvic organ prolapse, acute urinary tract infection, urolithiasis, or urinary tract malignancy. 2. The patient who has active skin disease on legs or not suitable for leg local injection. 3. Pregnant women. Method: 40 overactive bladder patients and 40 underactive bladder patients. The patients will receive 5% glucose 10ml local injection peripheral to posterior tibial nerve near ankle under ultrasound guidance once a week for 4 weeks, then the patients will be followed up once-a-month for 3 months. OverActive Bladder Symptom Score(OABSS), Core Lower Urinary Tract Symptom score(CLSS) questionnaire, 3-days voiding diary, and urine nerve growth factor are used for assessment.
Investigators
Jing-Dung, SHEN
Senior Urologist
Taichung Armed Forces General Hospital
Eligibility Criteria
Inclusion Criteria
- •Adults over 20 years-old.
- •The patient who meets the diagnostic criteria of overactive bladder or underactive bladder.
- •The patient who capable to complete 3-days voiding diary and the questionnaire.
Exclusion Criteria
- •Severe stress urinary incontinence or severe pelvic organ prolapse.
- •Acute urinary tract infection.
- •Active hematuria, urolithiasis, or neoplasm of urinary tract.
- •Acute skin lesion over the ankle injection site or the patient who could not tolerate ankle injection.
- •Pregnant women.
Outcomes
Primary Outcomes
Overactive Bladder Symptom Score
Time Frame: Week16
The improvement of overactive bladder symptom score (OABSS), OABSS ranged from 0 to 15, the higher score means more severity of overactive bladder.
Secondary Outcomes
- Cystometric bladder capacity(Week16)